At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19
In Brief
A Phase 2 clinical trial evaluating Standard Treatment and Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions for COVID-19. Completed, enrolled 120 participants across 1 site.
Detailed Summary
In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate, or severe pneumonia (according to the NIH guideline) were treated with conventional treatment regimens (controls) as well as in combination with oral administration of colchicine plus herbal phenolic monoterpene fractions (intervention arm). After randomization, each group received the mentioned treatments and were evaluated for different variables including mortality, hospitalization duration, intensive care unit (ICU) administration ratios as well as laboratory variables such as leukocytes and lymphocytes count. The follow-up period considered as 2 weeks after discharge. The mentioned variables were assessed as before and after receiving the treatment in each group as well as intergroup analysis for comparing both baseline and final values.
Study Details
Timeline
Interventions
Standard Treatment for COVID-19 based on National Recommendations
Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.